Adjunctive corticosteroids in non-HIV immunocompromised patients with Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis
Authors:
- Gustavo Rosales-ChavezGRGustavo Rosales-Chavez
- Pedro Martínez-AyalaPMPedro Martínez-Ayala
- Mauricio Alfredo Ambriz-AlarcónMAMauricio Alfredo Ambriz-Alarcón
- Brian Rafael Rubio-MoraBRBrian Rafael Rubio-Mora
- Judith Carolina De Arcos-JiménezJAJudith Carolina De Arcos-Jiménez
- Ana María López-YáñezALAna María López-Yáñez
- Alejandro Marín-Castañeda-BarónAMAlejandro Marín-Castañeda-Barón
- Andrés Alejandro Briseño-HernándezABAndrés Alejandro Briseño-Hernández
- José Rafael Villafán-BernalJVJosé Rafael Villafán-Bernal
- Jaime Alejandro Sánchez-GutiérrezJSJaime Alejandro Sánchez-Gutiérrez
- Jaime Briseno-RamirezJaime Briseno-Ramirez
Open Access
- 4 August 2026
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 13
Abstract
Background: Pneumocystis jirovecii pneumonia (PJP) in non-HIV immunocompromised adults carries 30%–60% mortality. Adjunctive corticosteroids are standard in HIV-PJP but remain contested in non-HIV PJP. Objectives: To determine whether adjunctive corticosteroids reduce mortality and invasive mechanical ventilation (IMV) in non-HIV PJP, and whether effect estimates differ between randomized and observational study designs. Design: Systematic review and meta-analysis. Data sources and methods: Six databases and two trial registers were searched from inception to February 7, 2026. Randomized and observational studies comparing adjunctive corticosteroids versus no corticosteroids or placebo in non-HIV adults with PJP were eligible. Random-effects meta-analyses (restricted maximum likelihood) of two co-primary outcomes included subgroup, sensitivity, E -value, and Grading of Recommendations Assessment analyses. Results: Twenty-eight studies were included (one randomized controlled trial (RCT), 27 observational; ∼ 5300 patients): 22 contributed corticosteroid-versus-no-corticosteroid comparisons and six contributed dose-comparison data only. Evidence was discordant by design (interaction p = 0 . 006 ): the RCT showed lower IMV (hazard ratio (HR) 0.36, 95% CI 0.14–0.90) and lower 90-day mortality (HR 0.59, 0.37–0.93); regression-adjusted observational studies suggested harm (odds ratio (OR) 1.56, 1.10–2.22); propensity-based estimates were null-compatible. Pre-specified mortality pools were non-significant short-term (OR 1.22, 0.88–1.70) and intermediate-term (OR 1.39, 0.85–2.29). Secondary infections ( k = 4 ): OR 1.04 (0.63–1.72); RCT 0.59 (0.32–1.06). E -values for RCT effects (3.44 IMV; 2.24 mortality) exceeded the 1.81 E -value of the adjusted observational mortality pool. Certainty was very low for pooled mortality and moderate for RCT outcomes. Conclusion: Reliable inference rests on the single RCT rather than the pooled observational estimate, which is discordant by design and most consistent with confounding by indication. In the RCT, corticosteroids did not significantly reduce 28-day mortality but lowered IMV and 90-day mortality and sped respiratory recovery, without clear excess secondary infections (low certainty). Corticosteroids may be considered for severe respiratory failure using the PIC (ClinicalTrials.gov NCT02944045) protocol; adequately powered confirmatory trials are needed. Trial registration : PROSPERO CRD420261304396.Keywords
This publication has 84 references indexed in Scilit:
- Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort studyIntensive Care Medicine, 2024
- Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020American Journal of Transplantation, 2023
- Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- Basics of meta‐analysis: I2 is not an absolute measure of heterogeneityResearch Synthesis Methods, 2017
- Methods to estimate the between‐study variance and its uncertainty in meta‐analysisResearch Synthesis Methods, 2015
- Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infectionCochrane Database of Systematic Reviews, 2015
- Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapiesJournal of Infection and Chemotherapy, 2012
- Comparison of Two Methods to Detect Publication Bias in Meta-analysisJAMA, 2006
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002